Avalo Therapeutics Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Avalo Therapeutics Inc.
Ownership: Public
Status: Active
Headquarters country: United States
Ticker symbol: AVTX
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001534120

Board of directors

Follow this board

Aaron Kantoff · Director
Since 2024
Garry Arthur Neil · Director · Chief Executive Officer
Since 2023
Gilla Kaplan · Director
Since 2023
Jonathan Goldman · Director
Since 2024
June Sherie Almenoff · Director
Since 2023
Kevin Robert Lind · Director
Since 2025
Magnus Persson · Director
Since 2023
Michael Thomas Heffernan · Director Overboarded
Since 2025
Mitchell Chan · Director
Since 2023
Rita Jain · Director Overboarded
Since 2025
Ron M. Philip · Director
Since 2026
Samantha Truex · Director
Since 2024

Chief executives

Garry Arthur Neil · CEO and Chairman of the Board

Dates unknown

Board connections

7 of this board's directors also sit on 14 other boards.

Shared director Other board Same sector

Celldex Therapeutics Inc.
via Garry Arthur Neil and Rita Jain
Actinium Pharmaceuticals Inc. (Delaware)
via June Sherie Almenoff
AnaptysBio Inc.
via Rita Jain
Apnimed Inc.
via Kevin Robert Lind
Biohaven Ltd.
via Michael Thomas Heffernan
Collegium Pharmaceutical Inc.
via Michael Thomas Heffernan
First Tracks Biotherapeutics Inc.
via Rita Jain
Harmony Biosciences Holdings Inc.
via Ron M. Philip
SAB Biotherapeutics Inc.
via Rita Jain
Tenax Therapeutics Inc.
via June Sherie Almenoff
Trevi Therapeutics Inc.
via Michael Thomas Heffernan
Tyra Biosciences Inc.
via Gilla Kaplan
Zura Bio Limited
via Garry Arthur Neil
enGene Therapeutics Inc.
via Michael Thomas Heffernan

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $8,106,797; 40 sales by 6 insiders

Date	Insider	Transaction	Shares	Price	Value
Aug 18, 2026	Sullivan Christopher Ryan Officer (Chief Financial Officer)	Option exercise	+31,031	$9.88	$306,586
Aug 18, 2026	Sullivan Christopher Ryan Officer (Chief Financial Officer)	Open-market sale	−31,031	$20.05	$622,324
Aug 17, 2026	Sullivan Christopher Ryan Officer (Chief Financial Officer)	Option exercise	+37,945	$9.88	$374,897
Aug 17, 2026	Mittie Doyle Officer (Chief Medical Officer)	Option exercise	+1,000	$12.65	$12,650
Aug 17, 2026	Sullivan Christopher Ryan Officer (Chief Financial Officer)	Option exercise	+2,876	$9.88	$28,415
Aug 17, 2026	Mittie Doyle Officer (Chief Medical Officer)	Open-market sale	−1,000	$20.00	$20,000
Aug 17, 2026	Sullivan Christopher Ryan Officer (Chief Financial Officer)	Open-market sale	−37,945	$19.85	$753,333
Aug 17, 2026	Sullivan Christopher Ryan Officer (Chief Financial Officer)	Open-market sale	−3,749	$19.94	$74,762
Aug 11, 2026	Riley Jennifer Officer (Chief Strategy Officer)	Open-market sale	−2,655	$19.59	$52,012
Aug 10, 2026	Mittie Doyle Officer (Chief Medical Officer)	Option exercise	+679	$8.04	$5,459
Aug 10, 2026	Mittie Doyle Officer (Chief Medical Officer)	Open-market sale	−679	$20.00	$13,580
Jul 27, 2026	Mittie Doyle Officer (Chief Medical Officer)	Option exercise	+1,000	$12.65	$12,650
Jul 27, 2026	Mittie Doyle Officer (Chief Medical Officer)	Open-market sale	−1,000	$20.00	$20,000
Jun 30, 2026	Mittie Doyle Officer (Chief Medical Officer)	Option exercise	+2,875	$12.65	$36,369
Jun 30, 2026	Mittie Doyle Officer (Chief Medical Officer)	Option exercise	+1,779	$8.04	$14,303

Reviews (0)

No reviews yet. Be the first to write one.